BCLI · Brainstorm Cell Therapeutics Inc.
$0.98
+0.10 (+11.36%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Management's plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed Aug 14, 2026
Market Cap
$10.92M
Shares
11.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.98
Open$0.85
Day$0.80–1.00
52W close$0.48–1.44
Avg vol 30d23K
Short int47K · 0.4% float · 2.5d
Short vol47%
Last earningsNov 14, 2025
DataOct 2024–Aug 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Oct 1, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+6%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
52%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+58%
trailing
YTD return
+78%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-86% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.43% of float · ▲ +3.0% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Squeeze score
36
low risk · 0–100
Fundamentals
EPS growth
+52%
Y/Y
Free cash flow
$-7.0M
Balance sheet
$938.0K
net debt
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-86% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.43% of float · ▲ +3.0% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $1 · 52%
Range high $1
vs 200-day avg +32%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCLI
this stock
Brainstorm Cell Therapeutics Inc.
|
$10.92M | +78.2% | — | — | 0.4% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
5
- % held
- 0.0%
- Net QoQ
- -390.5K sh
- Top holder
- OSAIC HOLDINGS, INC.
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Oct 1, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCLI | +19.5% | +8.9% | +58.1% | +8.9% | +78.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +19.1% | +4.4% | +44.3% | +5.0% | +64.3% |